Clinical Trials Arena on MSN12d
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
Nature3mon
Analysing differential gene expression in cancer
The discovery of the cyclin-dependent kinase inhibitor WAF1 (also known as p21) as a target gene of p53 by Bert Vogelstein's group provided another great example of the power of this conceptually ...
Nature5y
TMEPAI keeps TGFβ under control
A decrease in the level of proteins (including plasminogen activator inhibitor 1 (PAI-I; also known as SERPINE1) and cyclin-dependent kinase inhibitor 1 (p21; also known as CDKN1A)) encoded by ...